What is the risk reduction for clinical progression with combination treatment in the MTOPS study?
A- 66%***
B- 44%
C- 39%
D- 34%
E- 28%
Answer A:
The risk reduction for clinical progression is 66% with combination, 39% with doxazosin and 34% with finasteride.
A- 66%***
B- 44%
C- 39%
D- 34%
E- 28%
Answer A:
The risk reduction for clinical progression is 66% with combination, 39% with doxazosin and 34% with finasteride.
Labels
Urology